Opinion|Videos|July 22, 2024
Biologic Therapies for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
- Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Advertisement
Related to this article
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Navigating GLP-1 Access & Prior Authorizations: Amanda Velazquez, MD
5